TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07416604: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Emicizumab Prophylaxis in People With Hemophilia A

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 360 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$2,778,940

Rescue Site Savings

+$1,828,250

Unlock Full NCT07416604 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07416604 Rescue Dossier →